Polymorphism of pharmaceutical molecules: Perspectives on nucleation

Frontiers of Chemical Engineering in China

Volumn 4, Issue 1, 2010, Pages 37-44

  Lu, Jie ^a   Li, Zhen ^a   Jiang, Xiaolin ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Control; Discovery; Nucleation; Pharmaceutical molecules; Polymorph

Indexed keywords

EID: 77952886875     PISSN: 16737369     EISSN: 16737474     Source Type: Journal    
DOI: 10.1007/s11705-009-0294-2     Document Type: Review

References (41)

1. Wu H. An analysis on the production and sale of China's pharmaceutical industry. Chinese J Pharm, 2007, 38(4): A27-A34.
2. Shekunov B Y, York P. Crystallization processes in pharmaceutical technology and drug delivery design. J Cryst Growth, 2000, 211: 122-136.
3. Morissette S L, Almarsson Ö, Peterson M L, Remenar J F, Read M J, Lemmo A V, Ellis S, Cima M J, Gardner C R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev, 2004, 56: 275-300.
4. Datta S, Grant D J W. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov, 2004, 3: 42-57.
5. Sirota N N. Certain problems of polymorphism (I). Cryst Res Technol, 1982, 17: 661-691.
6. Doherty C, York P. Frusemide crystal forms-solid-state and physicochemical analyses. Int J Pharm, 1988, 47: 141-155.
7. Lu J, Rohani S. Polymorphic crystallization and transformation of the anti-viral/HIV drug stavudine. Org Process Res Dev, 2009, 13: 1262-1268.
8. Rodríguez-Caabeiro F, Criado-Fornelio A, Jimenez-Gonzalez A, Guzman L, Igual A, Perez A, Pujol M. Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms. Chemotherapy, 1987, 33: 266-271.
9. Swanepoel E, Liebenberg W, de Villiers MM. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur J Pharm Biopharm, 2003, 55: 345-349.
10. Sun C, Grant D J W. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res, 2001, 18: 274-280.
11. Mirmehrabi M, Rohani S. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci, 2005, 94: 1560-1576.
12. Aakeroy C B, Fasulo M E, Desper J. Cocrystal or salt: does it really matter? Mol Pharm, 2007, 4: 317-322.
13. Aitipamula S, Chow P S, Tan R B H. Dimorphs of a 1: 1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. Cryst Eng Comm, 2009, 11: 889-895.
14. Bernstein J, Hagler A T. Conformational polymorphism-the influence of crystal structure on molecular conformation. J Am Chem Soc, 1978, 100: 673-681.
15. Bernstein J, Davey R J, Henck J O. Concomitant polymorphs. Angew Chem Int Ed, 1999, 38: 3440-3461.
16. Datta S, Grant D J W. Effect of supersaturation on the crystallization of phenylbutazone polymorphs. Cryst Res Technol, 2005, 40: 233-242.
17. Gracin S, Rasmuson Å C. Polymorphism and crystallization of paminobenzoic acid. Cryst Growth Des, 2004, 4: 1013-1023.
18. Gu C H, Young V, Grant D J W. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci, 2001, 90: 1878-1890.
19. Weissbuch I, Lahav M, Leiserowitz L. Toward stereochentical control, monitoring, and understanding of crystal nucleation. Cryst Growth Des, 2002, 3: 125-150.
20. Davey R J, Allen K, Blagden N, Cross W I, Lieberman H F, Quayle M J, Righini S, Seton L, Tiddy G J T. Crystal engineering-nucleation, the key step. Cryst Eng Commun, 2002, 4: 257-264.
21. Khoshkhoo S, Anwar J. Crystallization of polymorphs-the effect of solvent. J Phys D-Appl Phys, 1993, 26: B90-B93.
22. Tao J, Jones K J, Yu L. Cross-nucleation between D-mannitol polymorphs in seeded crystallization. Cryst Growth Des, 2007, 7: 2410-2414.
23. Beckmann W, Otto W, Budde U. Crystallization of the stable polymorph of hydroxytriendione: seeding process and effects of purity. Org Process Res Dev, 2001, 5: 387-392.
24. Tanaka S, Ataka M, Kubota T, Soga T, Homma K, Lee W C, Tanokura M. The effect of amphiphilic additives on the growth and morphology of aspergillus niger acid proteinase a crystals. J Cryst Growth, 2002, 234: 247-254.
25. Rodríguez-Spong B, Price C P, Jayasankar A, Matzger A J, Rodríguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Deliv Rev, 2004, 56: 241-274.
26. Lee E H, Boerrigter S X M, Rumondor A C F, Chamarthy S P, Byrn S R. Formation and solid-state characterization of a salt-induced metastable polymorph of flufenamic acid. Cryst Growth Des, 2008, 8: 91-97.
27. Yang X, Lu J, Wang X J, Ching C B. Effect of sodium chloride on the nucleation and polymorphic transformation of glycine. J Cryst Growth, 2008, 310: 604-611.
28. Lang M D, Grzesiak A L, Matzger A J. The use of polymer heteronuclei for crystalline polymorph selection. J Am Chem Soc, 2002, 124: 14834-14835.
29. Bonafede S J, Ward M D. Selective nucleation and growth of an organic polymorph by ledge-directed epitaxy on a molecular-crystal substrate. J Am Chem Soc, 1995, 117: 7853-7861.
30. Hiremath R, Varney SW, Swift J A. Selective growth of a less stable polymorph of 2-iodo-4-nitroaniline on a self-assembled monolayer template. Chem Commun, 2004, 2676-2677.
31. Dressler D H, Mastai Y. Controlling polymorphism by crystallization on self-assembled multilayers. Cryst Growth Des, 2007, 126: 847-850.
32. Ha J M, Wolf J H, Hillmyer M A, Ward M D. Polymorph selectivity under nanoscopic confinement. J Am Chem Soc, 2004, 126: 3382-3383.
33. Garetz B A, Aber J E, Goddard N L, Young R G, Myerson A S. Nonphotochemical, polarization-dependent, laser-induced nucleation in supersaturated aqueous urea solutions. Phys Rev Lett, 1996, 77: 3475-3476.
34. Zaccaro J, Matic J, Myerson A S, Garetz B A. Nonphotochemical, laser-induced nucleation of supersaturated aqueous glycine produces unexpected gamma-polymorph. Cryst Growth Des, 2001, 1: 5-8.
35. Llinàs A, Goodman J M. Polymorph control: past, present and future. Drug Discov Today, 2008, 13(5-6): 198-210.
36. Di Profio G, Tucci S, Curcio E, Drioli E. Selective glycine polymorph crystallization by using microporous membranes. Cryst Growth Des, 2007, 7: 526-530.
37. Liu Y X, Wang X J, Lu J, Ching C B. Influence of the roughness, topography and physicochemical properties of chemically modified surfaces on the heterogeneous nucleation of protein crystals. J Phys Chem B, 2007, 111(50): 13971-13978.
38. Gardner C R, Almarsson Ö, Chen H, Morissette S L, Peterson M L, Zhang Z, Wang S, Lemmo A V, Gonzales-Zugasti J, Monagle J, Marchionna J, Ellis S J, McNulty C, Johnson A, Levinson D, Cima M J. Application of high-throughput technologies to drug substance and drug product development. Comput Chem Eng, 2004, 28: 943-953.
39. Lu J, Rohani S, Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Curr Med Chem, 2009, 16: 884-905.
40. Gavezzotti A. Computer simulations of organic solids and their liquid-state precursors. Faraday Discuss, 1997, 106: 63-77.
41. Gavezzotti A. Ten years of experience in polymorph prediction: what next? Cryst Eng Comm, 2002, 4: 343-347.